Novo Nordisk revenue and financials
kr 249.70Change from previous close: +1.69%Absolute change: +kr 4.15
In the fiscal year ended December 2025, Novo Nordisk reported revenue of kr 309.06B (+6.43% year over year). Net income was kr 102.43B, a net margin of 33.1%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +6.43%
- 2025 vs 2024
- Net income growth
- +1.43%
- 2025 vs 2024
- Net margin
- 33.1%
- 2024: 34.8%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | 542,902 | 465,630 | 314,486 | 241,257 | 194,508 | 144,922 | — |
| Current assets | 172,453 | 161,788 | 139,646 | 108,194 | 85,595 | 65,809 | — |
| Cash and equivalents | 26,464 | 15,655 | 14,392 | 12,653 | 10,719 | 12,226 | 15,411 |
| Short-term investments | 498 | 10,653 | 15,838 | 10,921 | 6,765 | — | — |
| Receivables | 89,186 | 88,305 | 75,261 | 57,505 | 46,799 | — | — |
| Inventory | 49,623 | 40,849 | 31,811 | 24,388 | 19,621 | — | — |
| Net property, plant and equipment | 208,378 | 161,680 | 90,961 | 66,671 | 55,362 | — | — |
| Goodwill | 19,845 | 20,017 | 4,464 | 4,615 | 4,346 | — | — |
| Other intangible assets | 110,208 | 90,804 | 55,942 | 46,324 | 38,825 | — | — |
| Long-term investments | 2,507 | 2,677 | 1,663 | 1,343 | 1,441 | — | — |
| Current liabilities | 215,661 | 217,614 | 169,655 | 120,940 | 99,516 | 70,273 | — |
| Accounts payable | 19,758 | 17,140 | 25,606 | 15,587 | 8,870 | — | — |
| Long-term debt | 130,958 | 102,787 | 27,006 | 1,500 | 26,645 | 10,356 | 4,483 |
| Total debt | 130,958 | 102,787 | 27,006 | 25,784 | — | — | — |
| Total liabilities | 348,855 | 322,144 | 207,925 | 157,771 | 123,762 | 81,597 | — |
| Total equity (incl. minority) | 194,047 | 143,486 | 106,561 | 83,486 | 70,746 | — | — |
| Retained earnings | 195,298 | 144,448 | 104,839 | 80,587 | 72,004 | — | — |